drug-pricing-drug-development 
STAT
APRIL 12, 2024
In response to controversy, a group of Colorado lawmakers is abandoning a bill that would have required a new state board — which is chartered with setting caps for the cost of medicines — to create exemptions for rare disease drugs. Continue to STAT+ to read the full story…
STAT
APRIL 10, 2024
… In an era when huge price hikes for prescription drugs are almost guaranteed to draw criticism, is there any circumstance when a 486% increase for a medicine might appear to be justified? Novartis plans to cut up to 680 jobs in its product development organization , Reuters notes. over the next two to three years.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
APRIL 11, 2024
Key drivers for the market include patent expirations of several biologic drugs and increasing demand for affordable biologic treatments, the author explained. Expirations of biologic patents has enabled manufacturers to enter the market and offer lower-cost alternatives of these drugs, according to the report. million by 2032, at 17.6
STAT
APRIL 9, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with an update on the biotech market, a look at the future of genome editing, and the evolving definition of “insider trading.” ” Read the rest…
STAT
APRIL 12, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with what is my final edition of The Readout on my last day at STAT.
STAT
APRIL 11, 2024
Damian here with a look at a biotech deal with a lengthy backstory, the tyranny of gas prices, and the latest shakeup at BIO. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Read the rest…
STAT
APRIL 12, 2024
Enjoy, and see you soon… Western drug makers are talking to alternative suppliers in response to draft U.S. legislation seeking to restrict an important Chinese drug developer and manufacturer over national security concerns , The Financial Times explains. Or simply plan the rest of your life. But be safe.
Expert insights. Personalized for you.
276 
Let's personalize your content